Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reported an executive share-related transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares within her GSK Executive Supplemental Savings Plan account. The transaction covered 9.455 ADS at a price of $50.5000 per ADS on 2026-05-07, executed on the New York Stock Exchange.
GSK plc reported an executive share-related transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares within her GSK Executive Supplemental Savings Plan account. The transaction covered 9.455 ADS at a price of $50.5000 per ADS on 2026-05-07, executed on the New York Stock Exchange.
GSK has entered an exclusive strategic collaboration with Sino Biopharmaceutical’s subsidiary CTTQ to support the launch of bepirovirsen for chronic hepatitis B in mainland China, where the disease affects an estimated 75 million people. Bepirovirsen is a potential first-in-class treatment under priority regulatory review in China, supported by positive phase III B-Well 1 and B-Well 2 trial results showing functional cure rates.
CTTQ, a hepatology leader with access to more than 5,000 medical centres, will handle importation, distribution, hospital access, and promotional activities. GSK will remain marketing authorisation holder and book sales of bepirovirsen supplied to CTTQ under agreed supply terms for an initial 5.5-year period. The agreement also allows GSK to review certain SBP Group early-stage pipeline assets for possible collaborations outside China.
GSK has entered an exclusive strategic collaboration with Sino Biopharmaceutical’s subsidiary CTTQ to support the launch of bepirovirsen for chronic hepatitis B in mainland China, where the disease affects an estimated 75 million people. Bepirovirsen is a potential first-in-class treatment under priority regulatory review in China, supported by positive phase III B-Well 1 and B-Well 2 trial results showing functional cure rates.
CTTQ, a hepatology leader with access to more than 5,000 medical centres, will handle importation, distribution, hospital access, and promotional activities. GSK will remain marketing authorisation holder and book sales of bepirovirsen supplied to CTTQ under agreed supply terms for an initial 5.5-year period. The agreement also allows GSK to review certain SBP Group early-stage pipeline assets for possible collaborations outside China.
GSK plc is launching the fifth and final tranche of its previously announced £2 billion share buyback programme. The company has already repurchased 114,436,378 Ordinary Shares for about £1.82 billion, and this last tranche will be up to approximately £0.18 billion.
The final tranche is scheduled to run from 11 May 2026 to 26 June 2026 under a non-discretionary agreement with Citi. GSK states that the buyback is intended to return excess capital, reduce share capital, and is expected to enhance earnings per share, with shares bought in this tranche to be held as Treasury shares.
GSK plc is launching the fifth and final tranche of its previously announced £2 billion share buyback programme. The company has already repurchased 114,436,378 Ordinary Shares for about £1.82 billion, and this last tranche will be up to approximately £0.18 billion.
The final tranche is scheduled to run from 11 May 2026 to 26 June 2026 under a non-discretionary agreement with Citi. GSK states that the buyback is intended to return excess capital, reduce share capital, and is expected to enhance earnings per share, with shares bought in this tranche to be held as Treasury shares.
GSK plc reported the results of its 26th hybrid Annual General Meeting, where shareholders could participate in person or online. All 25 resolutions were passed on a poll, including the receipt and adoption of the 2025 Annual Report and approval of the annual remuneration report and policy.
Support for the 2025 Annual Report reached 3,073,839,952 votes in favour, or 99.25% of votes cast, with total votes on that resolution representing 76.38% of issued share capital. All directors standing for election or re-election were backed by large majorities, and the auditor’s re-appointment and remuneration were also strongly approved.
Shareholders granted authorities to allot shares, disapply pre-emption rights, and purchase the company’s own shares, with each relevant special resolution receiving well over the required 75% majority. Overall AGM participation, including votes cast and withheld, represented 76.59% of GSK’s issued share capital excluding treasury shares.
GSK plc reported the results of its 26th hybrid Annual General Meeting, where shareholders could participate in person or online. All 25 resolutions were passed on a poll, including the receipt and adoption of the 2025 Annual Report and approval of the annual remuneration report and policy.
Support for the 2025 Annual Report reached 3,073,839,952 votes in favour, or 99.25% of votes cast, with total votes on that resolution representing 76.38% of issued share capital. All directors standing for election or re-election were backed by large majorities, and the auditor’s re-appointment and remuneration were also strongly approved.
Shareholders granted authorities to allot shares, disapply pre-emption rights, and purchase the company’s own shares, with each relevant special resolution receiving well over the required 75% majority. Overall AGM participation, including votes cast and withheld, represented 76.59% of GSK’s issued share capital excluding treasury shares.
FMR LLC reported beneficial ownership of $0 234,936,060.81 shares of GSK PLC common stock, representing 5.8% of the class as disclosed for the period ending 03/31/2026. The filing lists sole voting power of 171,486,572.69 shares and sole dispositive power of 234,936,060.81 shares. The schedule notes that one or more other persons may have rights to dividends or sale proceeds and refers to Exhibit 99 and an attached power of attorney.
FMR LLC reported beneficial ownership of $0 234,936,060.81 shares of GSK PLC common stock, representing 5.8% of the class as disclosed for the period ending 03/31/2026. The filing lists sole voting power of 171,486,572.69 shares and sole dispositive power of 234,936,060.81 shares. The schedule notes that one or more other persons may have rights to dividends or sale proceeds and refers to Exhibit 99 and an attached power of attorney.
GSK plc granted a deferred investment award to new Chief People Officer and Executive Committee member Roanne Parry. The award is over notional Ordinary Shares, referenced to 35,507.628 shares at a price of £19.01 per share, and is intended to align long term with shareholders.
The award vests in two stages, with 34.22% scheduled to vest on 31 August 2028 and 65.78% on 31 August 2029, provided Ms Parry has not resigned or been terminated for cause. Dividends will accrue during the vesting period, and the benefit will be settled in cash on vesting.
GSK plc granted a deferred investment award to new Chief People Officer and Executive Committee member Roanne Parry. The award is over notional Ordinary Shares, referenced to 35,507.628 shares at a price of £19.01 per share, and is intended to align long term with shareholders.
The award vests in two stages, with 34.22% scheduled to vest on 31 August 2028 and 65.78% on 31 August 2029, provided Ms Parry has not resigned or been terminated for cause. Dividends will accrue during the vesting period, and the benefit will be settled in cash on vesting.
GSK plc reported its share capital and voting rights as of 30 April 2026. The company had 4,316,202,660 ordinary shares of 31¼ pence each in issue, including 261,378,286 shares held in treasury. This leaves a total of 4,054,824,374 voting rights for shareholder disclosure calculations.
GSK plc reported its share capital and voting rights as of 30 April 2026. The company had 4,316,202,660 ordinary shares of 31¼ pence each in issue, including 261,378,286 shares held in treasury. This leaves a total of 4,054,824,374 voting rights for shareholder disclosure calculations.
GSK plc files a Form 6-K reporting a TR-1 notification that a major holder has 4.930000% of its voting rights, representing 200,296,898 voting rights in total. These are held through ordinary shares and ADRs, with no additional voting rights linked to financial instruments.
The filing shows 88,958,040 voting rights (2.190000%) attached to ordinary shares and 111,338,858 voting rights (2.740000%) through ADRs, together making up the reported 4.930000% position.
GSK plc files a Form 6-K reporting a TR-1 notification that a major holder has 4.930000% of its voting rights, representing 200,296,898 voting rights in total. These are held through ordinary shares and ADRs, with no additional voting rights linked to financial instruments.
The filing shows 88,958,040 voting rights (2.190000%) attached to ordinary shares and 111,338,858 voting rights (2.740000%) through ADRs, together making up the reported 4.930000% position.
GSK plc reported two senior personnel share transactions. Independent Non-Executive Director Wendy Becker purchased 4,000 Ordinary Shares at £19.6291 each on the London Stock Exchange on 2026-04-29. Ordinary Shares have a nominal value of 31¼ pence.
Chief People Officer Diana Conrad acquired 12.874 American Depositary Shares at $54.5854 per ADS under the GSK pension plan on the New York Stock Exchange on 2026-04-27. Both transactions are disclosed as initial notifications of dealings by persons discharging managerial responsibilities.
GSK plc reported two senior personnel share transactions. Independent Non-Executive Director Wendy Becker purchased 4,000 Ordinary Shares at £19.6291 each on the London Stock Exchange on 2026-04-29. Ordinary Shares have a nominal value of 31¼ pence.
Chief People Officer Diana Conrad acquired 12.874 American Depositary Shares at $54.5854 per ADS under the GSK pension plan on the New York Stock Exchange on 2026-04-27. Both transactions are disclosed as initial notifications of dealings by persons discharging managerial responsibilities.
GSK reported Q1 2026 results showing steady growth driven by Specialty Medicines. Turnover reached £7.6 billion, up 5% at constant exchange rates (CER), with Specialty Medicines up 14% CER to £3.2 billion, led by HIV, respiratory and oncology products.
Core operating profit rose 10% CER to £2.65 billion, with core EPS up 9% CER to 46.5p, helped by a richer product mix, lower SG&A and higher royalty income, partly offset by increased R&D. Free cash flow was £815 million, while net debt increased to £15.6 billion following acquisitions, dividends and buybacks.
GSK declared a 17p Q1 dividend and expects a 70p dividend for 2026. The company affirmed 2026 guidance of 3–5% turnover growth and 7–9% growth in both core operating profit and core EPS at CER, and reiterated a 2031 sales outlook of more than £40 billion. GSK also highlighted multiple new product approvals, a broad late‑stage pipeline and a US agreement providing Section 232 tariff relief on patented medicines through 20 January 2029.
GSK reported Q1 2026 results showing steady growth driven by Specialty Medicines. Turnover reached £7.6 billion, up 5% at constant exchange rates (CER), with Specialty Medicines up 14% CER to £3.2 billion, led by HIV, respiratory and oncology products.
Core operating profit rose 10% CER to £2.65 billion, with core EPS up 9% CER to 46.5p, helped by a richer product mix, lower SG&A and higher royalty income, partly offset by increased R&D. Free cash flow was £815 million, while net debt increased to £15.6 billion following acquisitions, dividends and buybacks.
GSK declared a 17p Q1 dividend and expects a 70p dividend for 2026. The company affirmed 2026 guidance of 3–5% turnover growth and 7–9% growth in both core operating profit and core EPS at CER, and reiterated a 2031 sales outlook of more than £40 billion. GSK also highlighted multiple new product approvals, a broad late‑stage pipeline and a US agreement providing Section 232 tariff relief on patented medicines through 20 January 2029.